Discover trends, market shifts, and competitive outlooks for the stelara (ustekinumab) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Fast Is The Stelara (Ustekinumab) Market Expected to Grow Between 2025 And 2029?

In recent times, the market for Stelara (ustekinumab) has seen robust growth. It is projected to escalate from $11,177.34 million in 2024 to $11,850.79 million in 2025, marking a compound annual growth rate (CAGR) of 6.0%. The notable growth during the historical period can be credited to increased healthcare expenditure, the expansion of specialty pharmaceutical distribution channels, broadening clinical trial initiatives, investment in research and innovation, and the rising use of telemedicine for easier treatment access.

In the coming years, the market size of Stelara (ustekinumab) is projected to undergo significant expansion, growing to $14,768.48 million in 2029 with a compound annual growth rate (CAGR) of 5.7%. The escalation during the forecast period can be credited to a broader range of indications for Stelara, the growing prevalence of autoimmune diseases, superior efficacy in resistant cases in comparison to other options, enhanced patient and healthcare provider awareness, and increased emphasis on tailored medicine. Foreseeable trends for this period encompass the adoption of biologic therapies, the evolution of enhanced drug delivery systems, data-guided healthcare structures, collaborative and licensing alliances amongst pharmaceutical corporations, and breakthroughs in biologic manufacturing technologies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Stelara (Ustekinumab) Market?

The increase in the incidence of psoriasis patients is anticipated to boost the stelara (ustekinumab) market’s expansion in the future. These patients have an autoimmune disorder that speeds up skin cell regeneration, causing red, flaky patches. The escalated prevalence of this condition can be linked to factors such as more accurate diagnosis, environmental causative agents, genetic tendencies, and a growing elderly population. Stelara (ustekinumab) works by thwarting interleukin-12 and interleukin-23, thereby assisting psoriasis patients by effectively mitigating inflammation and plaque accumulation. This leads to better skin clearance and lasting symptom control, ultimately improving their life quality. For example, a publication by the National Library of Medicine, a medical library based in the US, revealed that the incidence of psoriasis escalated to 0.221% in 2022, with a report of 6,930 PsA cases among a population of 3,133,500 in May 2024. Hence, the increased incidence of psoriasis patients is projected to drive the expansion of the stelara (ustekinumab) market.

Which Segments in the Stelara (Ustekinumab) Offer the Most Growth?

The stelara (ustekinumab)market covered in this report is segmented –

1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn’s Disease; Ulcerative Colitis; Other Indications

2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

4) By End User: Pediatric; Adult; Geriatric

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19935&type=smp

What Are the Fastest-Growing Geographies in the Stelara (Ustekinumab) Market?

North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Stelara (Ustekinumab) Industry?

One prominent trend in the Stelara (Ustekinumab) market is the introduction of unique products, such as biosimilars to Stelara, designed to offer affordable treatment solutions for individuals with chronic inflammatory diseases. These Stelara biosimilars are biologically comparable medicines designed to mimic the healing impacts of Stelara (Ustekinumab) by targeting IL-12 and IL-23 to combat autoimmune disorders like psoriasis and psoriatic arthritis. To illustrate, in October 2024, Accord BioPharma Inc., an American biopharmaceutical firm, garnered approval from the U.S. Food and Drug Administration (FDA) for IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is noteworthy for its extensive indications, providing therapies for mature patients dealing with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to enormously active Crohn’s disease, and ulcerative colitis. Remarkably, it is also certified for use in pediatric patients over 6 years old with moderate to severe plaque psoriasis and active psoriatic arthritis, showcasing its flexibility across different ages. This comprehensive applicability situates IMULDOSA as a useful alternative for managing a myriad of immune-driven inflammatory diseases.

View the full report here:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

What Are the Key Elements That Define the Stelara (Ustekinumab) Market?

Stelara (Ustekinumab) is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), key proteins involved in inflammatory and autoimmune responses. It is widely used to treat conditions such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19935

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model